Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
Int J Dermatol. 2021 Feb;60(2):190-195. doi: 10.1111/ijd.15183. Epub 2020 Sep 29.
Atopic dermatitis (AD) is an allergic disease that affects individuals of various ages. Recently, the IL-4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has been reported to reduce several markers of AD, including the serum levels of thymus and activation-regulated chemokine (TARC/CCL17), blood lactate dehydrogenase (LDH), and serum total immunoglobulin E (IgE).
We retrospectively reviewed data from 40 AD patients who were treated with dupilumab. Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), body surface area (BSA) scores, TARC, LDH, total IgE, and eosinophil count in peripheral blood were assessed for a total of 32 weeks.
The EASI, IGA, and BSA scores improved significantly with treatment, indicating a reduction in AD severity. Serum TARC and LDH levels also significantly decreased with treatment. Serum IgE levels were unchanged at 2 weeks of treatment but decreased significantly between 4 and 32 weeks. The number of eosinophils in the peripheral blood decreased at 4, 16, and 32 weeks after treatment initiation.
Several studies have reported that serum TARC, LDH, and total IgE levels are reduced by dupilumab treatment. Our real-world data are the first to demonstrate a reduction in blood eosinophilia in patients who receive clinical treatment with dupilumab.
特应性皮炎（AD）是一种影响各年龄段人群的过敏性疾病。最近，IL-4/13 抑制剂度普利尤单抗已获得监管部门批准，可用于 AD 患者的临床治疗。据报道，度普利尤单抗可降低 AD 的多个标志物，包括血清胸腺和激活调节趋化因子（TARC/CCL17）、血液乳酸脱氢酶（LDH）和血清总免疫球蛋白 E（IgE）水平。
我们回顾性分析了 40 例接受度普利尤单抗治疗的 AD 患者的数据。共评估了 32 周的湿疹面积和严重程度指数（EASI）、研究者全球评估（IGA）、体表面积（BSA）评分、TARC、LDH、总 IgE 和外周血嗜酸性粒细胞计数。
治疗后 EASI、IGA 和 BSA 评分显著改善，表明 AD 严重程度降低。血清 TARC 和 LDH 水平也随治疗显著降低。治疗 2 周时血清 IgE 水平无变化，但在 4 至 32 周时显著降低。治疗开始后 4、16 和 32 周时外周血嗜酸性粒细胞数量减少。
多项研究报告称，度普利尤单抗治疗可降低血清 TARC、LDH 和总 IgE 水平。我们的真实世界数据首次证明，接受度普利尤单抗临床治疗的患者血液嗜酸性粒细胞减少。
